查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011261

隐球菌病治疗市场：2026-2032年全球市场预测（按药物类别、给药途径、患者类型、最终用户和分销管道划分）

Cryptococcosis Treatment Market by Drug Class, Administration Route, Patient Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，隐球菌病治疗市场价值将达到 82.4 亿美元，到 2026 年将成长至 87.1 亿美元，到 2032 年将达到 125 亿美元，复合年增长率为 6.12%。

主要市场统计数据
基准年 2025 82.4亿美元
预计年份：2026年 87.1亿美元
预测年份 2032 125亿美元
复合年增长率 (%) 6.12%

一份策略概述，清楚地展现了当今影响隐球菌病治疗的临床复杂性、供应链现实和相关人员需求。

隐球菌病是一种具有重要临床意义的真菌感染疾病，对免疫力缺乏患者的影响尤其显着，并持续受到临床医生、采购负责人和政策制定者的关注。目前，隐球菌病的治疗现况受到有效药物数量有限、给药途径复杂、抗药性模式不断演变以及合併症管理等因素的限制。因此，相关人员必须在临床最佳实践与药物可近性、给药途径以及患者个别因素等实际限制之间取得平衡。

临床创新、供应链重组和管理主导实践如何共同重新定义隐球菌病治疗路径和相关人员的角色。

隐球菌病的治疗格局正在经历一场变革，这主要得益于药物治疗的进步、监管机构对抗菌药物合理使用的日益重视以及全球药品供应链的结构性转变。新型抗真菌製剂和改良的脂质体递送系统彻底改变了重症疾病的治疗选择。同时，人们也越来越关注抗真菌药物的合理使用，这促使临床医生在住院和门诊环境中改进治疗方案的顺序。此外，製药公司也在努力应对价格压力和不断变化的报销模式，这些因素正在影响其在产能和製剂创新方面的投资。

本研究评估了 2025 年关税环境将如何加剧整个抗真菌药物供应链的供应链重组、筹资策略和区域製造应对措施。

2025年实施的关税调整的累积影响暴露了供应链中原有的脆弱性，加速了製造商、经销商和医疗保健系统采取战略应对措施。活性成分、特殊脂质体辅料和成品药进口成本的上升加剧了采购预算的压力，促使终端用户探索替代筹资策略。为此，製造商正在审查製造地和采购政策，以降低关税波动带来的风险，并确保关键抗真菌药物的供应。

将药物类别、临床环境、给药途径、分销管道和患者类型与治疗和获取的不同趋势联繫起来的详细細項分析。

细分市场分析揭示了不同治疗领域、医疗机构、给药途径、分销管道和患者类型之间的不同趋势，每种趋势都对临床实践和商业化产生独特的影响。依药物类别划分，市场可分为Azole、Flucytosine和Polyenes，并进行深入研究。在Azole类药物中，市场格局透过Fluconazole、Posaconazole和Voriconazole等特定药物进行进一步分析。在Polyenes药物中，去氧胆酸两性双性杀霉素B和脂质体两性双性杀霉素B製剂均值得关注。这些差异会影响临床选择。口服Azole支援长期抑制和门诊管理，而Polyenes和Flucytosine在诱导治疗和重症疾病通讯协定中发挥核心作用。

区域临床需求、监管多样性和製造地如何相互作用并影响全球主要市场的准入、采购和治疗方法选择。

区域趋势对治疗的可近性、采购惯例和临床管理模式有着至关重要的影响。在美洲，医院准备和大规模三级医疗中心的存在等政策重点正在塑造对肠外诱导治疗的需求，并影响与生产商的合约谈判。从住院治疗过渡到门诊治疗是一项关键优先事项，这正在重塑临床医生和药剂师管理降阶治疗和药物依从性支持的方式。

对正在重塑隐球菌病治疗的取得和临床实施的製药公司、经销商和服务供应商进行竞争定位和能力分析。

在该治疗领域主要企业凭藉其製剂技术、无菌生产能力、全球分销网络和合规性脱颖而出。一些製造商正大力投资脂质体製剂技术，以提高耐受性并降低肾毒性，这对于加护病房和移植科室的应用至关重要。另一些製造商则凭藉强大的学名药产品组合和完善的原料药成分 (API) 采购体系脱颖而出，从而能够以具有成本竞争力的价格向门诊和资源有限的医疗机构供应药物。

为领导者提供切实可行的策略建议，以加强供应链韧性，使产品组合与临床路径保持一致，并优化护理过渡各个阶段的商业化。

产业领导者应优先考虑一系列切实可行的策略，使临床优先事项与具有韧性的供应链和高度灵活的商业模式一致。首先，采用双重采购模式生产製造，并投资区域生产能力，可以降低单一来源风险，减轻贸易波动风险。其次，使产品系列与治疗路径要求相匹配，包括确保提供静脉诱导治疗和口服维持治疗方案，有助于在住院和门诊环境中实现治疗的连续性。第三，加强与专科药局和居家输液服务提供者的伙伴关係，有助于安全地过渡到后续治疗，并提高长期抑制治疗的用药依从性。

为了检验实际见解，我们采用透明的混合方法研究途径，将对临床医生和供应链相关人员的访谈与监管和技术文献结合。

本研究整合了一手和二手资料，旨在全面了解临床实践、供应链动态和商业性行为。一手资料包括对临床医生、药房经理、采购负责人以及製造和分销部门高管进行结构化访谈，以识别实际挑战、治疗决策因素和采购惯例。这些定性见解辅以对同行评审的临床文献、监管指南、产品标籤以及公开的生产和贸易数据的二手分析，以确保技术准确性和背景深度。

简洁的整合强调製造、临床实践和采购等相关人员之间的协作努力，以确保获得治疗并优化患者疗效。

总之，隐球菌病的治疗面临临床复杂性和操作脆弱性的双重挑战，需要生产者、医疗系统和临床团队通力合作。治疗方法的选择受药物类别、给药途径可行性和患者个别因素的影响，而治疗的可近性则取决于区域製造地、筹资策略和不断变化的贸易政策。关税波动和供应链重组带来的累积压力凸显了积极风险管理的必要性，包括采购管道多元化以及住院和门诊护理管道之间更紧密的协调。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：隐球菌病治疗市场：依药物类别划分

  • Azole
    • Fluconazole
    • Posaconazole
    • Voriconazole
  • Flucytosine
  • Polyenes
    • 双性杀霉素B脱氧胆酸盐
    • 脂质体Amphotericin B

第九章：隐球菌病治疗市场（依给药途径划分）

  • 静脉
    • 中央静脉导管
    • 外围
  • 口服
    • 悬浮液
    • 药片

第十章：依患者类型分類的隐球菌病治疗市场

  • 爱滋病毒感染者
  • 未感染爱滋病毒的人
    • 正常的免疫功能
    • 移植患者

第十一章 隐球菌病治疗市场：依最终用户划分

  • 诊所
    • 门诊部
    • 专科诊所
  • 居家照护
  • 医院

第十二章 隐球菌病治疗市场：依分销管道划分

  • 离线
  • 在线的

第十三章：隐球菌病治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 隐球菌病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 隐球菌病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国隐球菌病治疗市场

第十七章：中国隐球菌病治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amplyx Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • F2G Limited
  • Flynn Pharma Ltd.
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Limited
  • Janssen Pharmaceuticals, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • NuCare Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sigmapharm Laboratories LLC
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4316E4E894B8

The Cryptococcosis Treatment Market was valued at USD 8.24 billion in 2025 and is projected to grow to USD 8.71 billion in 2026, with a CAGR of 6.12%, reaching USD 12.50 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.24 billion
Estimated Year [2026] USD 8.71 billion
Forecast Year [2032] USD 12.50 billion
CAGR (%) 6.12%

A clear and strategic overview that frames the clinical complexity, supply chain realities, and stakeholder imperatives shaping cryptococcosis treatment today

Cryptococcosis remains a clinically significant fungal infection that disproportionately affects immunocompromised populations, prompting sustained attention from clinicians, procurement specialists, and policy makers. The therapeutic landscape is shaped by a limited number of efficacious agents, complex administration requirements, and evolving patterns of resistance and co-morbidity management. As a result, stakeholders must reconcile clinical best practices with real-world constraints such as drug availability, route-of-administration considerations, and patient-specific factors.

In recent years, health systems have reoriented toward more resilient supply chains and closer alignment between hospital formularies and outpatient care pathways. These shifts have influenced prescribing behavior and institutional preparedness, especially in settings that manage high volumes of HIV-infected and transplant patients. Consequently, decision-makers face a dual imperative: ensuring uninterrupted access to first-line and salvage therapies while optimizing outcomes across diverse clinical settings. This introduction frames the core tension between clinical necessity and operational feasibility, establishing the foundation for the more detailed analyses that follow.

How clinical innovation, supply chain reconfiguration, and stewardship-driven practices are jointly redefining cryptococcosis therapy pathways and stakeholder roles

The landscape for cryptococcosis treatment is undergoing transformative shifts driven by advances in pharmacotherapy, regulatory emphasis on antimicrobial stewardship, and structural changes in global pharmaceutical supply chains. Newer antifungal formulations and improved liposomal delivery systems have reshaped treatment options for severe disease, while heightened attention to antifungal stewardship is refining how clinicians sequence therapies across inpatient and outpatient settings. At the same time, manufacturers are adapting to pricing pressures and evolving reimbursement models, which influence investment in manufacturing capacity and formulation innovation.

Technological developments in drug delivery and diagnostics are influencing care pathways. Rapid diagnostics and improved biomarker monitoring enable earlier detection and may alter the duration and intensity of therapy, which in turn affects demand dynamics across administration routes. Parallel to clinical innovation, health systems are prioritizing supplier diversification and inventory resilience, prompting investments in local manufacturing and strategic contracting. Taken together, these dynamics are converging to create a more nuanced, clinically responsive environment for cryptococcosis treatment that requires integrated responses across clinical teams, supply chain managers, and commercial stakeholders.

Assessing how the 2025 tariff environment has intensified supply chain realignment, procurement strategies, and regional manufacturing responses across antifungal supply chains

The cumulative impact of tariff adjustments instituted in 2025 has accentuated pre-existing supply chain vulnerabilities and accelerated strategic responses among manufacturers, distributors, and health systems. Higher import costs for active pharmaceutical ingredients, specialized liposomal excipients, and finished drug products have increased pressure on procurement budgets and encouraged end users to seek alternative sourcing strategies. In response, manufacturers have re-evaluated their manufacturing footprints and sourcing policies to mitigate exposure to tariff volatility and to preserve access to critical antifungal agents.

Consequently, some suppliers have accelerated localization and dual-sourcing initiatives, investing in regional production hubs and qualifying additional contract manufacturers to maintain continuity of supply. These actions reduce single-source exposure but require capital expenditure, regulatory approvals, and time to qualify new facilities. For purchasers, the tariff landscape has prompted more stringent supplier performance monitoring and an increased use of long-term agreements with price-stability mechanisms. Clinicians and pharmacy leaders have also revisited inventory policies, balancing just-in-time procurement with strategic buffer stocks to manage short-term disruptions. Overall, the tariff environment has served as a catalyst for structural change, encouraging stakeholders to adopt more resilient, albeit sometimes costlier, approaches to ensuring uninterrupted access to treatment.

In-depth segmentation insights tying drug classes, clinical settings, administration routes, distribution channels, and patient types to differentiated treatment and access dynamics

Segmentation analysis reveals differentiated dynamics across therapeutic classes, care settings, administration routes, distribution channels, and patient types, each of which carries distinct implications for clinical practice and commercialization. Based on drug class, the market is studied across Azoles, Flucytosine, and Polyenes; within Azoles, the landscape is further examined through specific agents such as Fluconazole, Posaconazole, and Voriconazole, while Polyenes merit attention for both Amphotericin B Deoxycholate and Liposomal Amphotericin B formulations. These distinctions inform clinical choice, as oral azoles support long-term suppression and outpatient management, whereas polyene formulations and flucytosine are central to induction and severe disease protocols.

Based on End User, the market is studied across Clinics, Home Care, and Hospitals; Clinics are further differentiated into Outpatient Clinics and Specialist Clinics, reflecting where patients interface with structured monitoring and initiation of therapy. Based on Administration Route, the market is studied across Intravenous and Oral; Intravenous administration is further parsed into Central Line and Peripheral options, while Oral delivery is evaluated by Suspension and Tablet formulations. These nuances affect logistics, nursing resource allocation, and patient adherence strategies. Based on Distribution Channel, the market is studied across Offline and Online, highlighting the growing role of e-commerce and specialty pharmacy channels in improving outpatient access. Finally, based on Patient Type, the market is studied across HIV Infected and Non-HIV Infected populations; Non-HIV Infected groups are further segmented into Immunocompetent and Transplant Patients, each presenting distinct comorbidity profiles and therapeutic risk-benefit calculations. Integrating these segmentation lenses enables a granular understanding of usage patterns, formulary decisions, and the operational trade-offs that guide therapy selection across care settings.

How regional clinical imperatives, regulatory diversity, and manufacturing footprints interact to shape access, procurement, and treatment choices across major global markets

Regional dynamics exert a decisive influence on treatment availability, procurement practices, and clinical management paradigms. In the Americas, policy emphasis on hospital preparedness and the presence of large tertiary care centers shape demand for parenteral induction therapies and influence contract negotiations with manufacturers. Transitioning care from inpatient to outpatient settings is a key priority, and this reshapes how clinicians and pharmacists manage step-down therapy and adherence support.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable health infrastructure create a mosaic of access realities. Countries with advanced diagnostics and reimbursement pathways have adopted newer formulations more rapidly, while resource-constrained settings prioritize cost-effective, readily available agents and pragmatic protocols that account for limited inpatient capacity. Cross-border procurement and donor-supported supply channels remain important in many jurisdictions. In the Asia-Pacific region, manufacturing capacity, particularly for generic azoles and certain APIs, is concentrated in a handful of producer countries, influencing regional supply dynamics and pricing. At the same time, several health systems are investing in diagnostic capacity and regional distribution networks to improve early detection and outpatient continuity of care. These regional patterns highlight the need for strategies tailored to local regulatory, clinical, and supply-chain contexts, while acknowledging the transnational nature of manufacturing and distribution interdependencies.

Competitive positioning and capability analysis of manufacturers, distributors, and service providers that are reshaping therapeutic access and clinical adoption in cryptococcosis care

Key companies operating in this therapeutic area are differentiated by their capabilities in formulation expertise, sterile manufacturing, global distribution networks, and regulatory compliance. Some manufacturers have invested heavily in liposomal formulation technology to improve tolerability and reduce nephrotoxicity, which has implications for uptake in intensive care and transplant units. Other firms have differentiated through robust generics portfolios and extensive API sourcing arrangements that support cost-competitive supply to outpatient and resource-constrained settings.

Distributors and specialty pharmacies play a pivotal role in bridging hospital and community care, particularly where complex intravenous therapies transition to home infusion or ambulatory infusion centers. Clinical service providers and contract manufacturers that can ensure consistent quality, scalable production, and accelerated regulatory filing pathways are increasingly valuable partners. In addition, diagnostic and digital health firms that enable earlier detection and remote monitoring contribute to more efficient treatment pathways. Overall, organizational strength is defined by the ability to integrate clinical evidence, manufacturing reliability, and responsive commercial models to support both acute-care induction and long-term suppression strategies across diverse patient populations.

Actionable strategic recommendations for leaders to strengthen supply resilience, align portfolios with clinical pathways, and optimize commercialization across care transitions

Industry leaders should prioritize a set of actionable strategies that align clinical priorities with resilient supply and adaptive commercial models. First, investing in manufacturing dual-sourcing and regional production capacity will reduce single-source risk and mitigate trade-related volatility. Second, aligning product portfolios with care pathway requirements-such as ensuring availability of both intravenous induction options and oral consolidation therapies-will support continuity across inpatient and outpatient settings. Third, strengthening partnerships with specialty pharmacies and home-infusion providers will facilitate safe transitions of care and improve adherence for long-term suppression regimens.

Moreover, leaders should embed robust stewardship and diagnostics into their commercialization plans to support appropriate use and to protect clinical efficacy. Contracting strategies that include price-stability clauses, inventory sharing arrangements, and outcomes-linked agreements can stabilize procurement budgets while maintaining access. Finally, targeted investments in clinician education, formulary support, and patient adherence programs will accelerate uptake in appropriate settings and improve outcomes. Collectively, these recommendations provide a pragmatic blueprint for converting strategic insight into operational resilience and improved patient care.

A transparent mixed-methods research approach combining clinician and supply-chain interviews with regulatory and technical literature to validate actionable insights

This research synthesizes primary and secondary inputs to produce a comprehensive understanding of clinical practice, supply-chain dynamics, and commercial behaviors. Primary research included structured interviews with clinicians, pharmacy directors, procurement officers, and manufacturing and distribution executives to capture real-world operational challenges, therapeutic decision drivers, and procurement practices. These qualitative insights were supplemented by secondary analysis of peer-reviewed clinical literature, regulatory guidance, product labels, and public-domain manufacturing and trade data to ensure technical accuracy and contextual depth.

Triangulation methods were applied to reconcile divergent perspectives and to validate recurring patterns across geographies and care settings. Where appropriate, regulatory timelines and manufacturing capacity constraints were mapped against clinical treatment protocols to identify potential bottlenecks and points of intervention. The methodology prioritized transparency in assumptions and robustness in cross-validation to ensure that conclusions reflect observable trends and expert judgment rather than speculative projection.

A concise synthesis emphasizing coordinated action across manufacturing, clinical, and procurement stakeholders to secure treatment access and optimize patient outcomes

In summary, cryptococcosis treatment is situated at the intersection of clinical complexity and operational fragility, requiring coordinated action across manufacturers, health systems, and clinical teams. Therapeutic choices hinge on drug class selection, administration route feasibility, and patient-specific factors, while access is shaped by regional manufacturing footprints, procurement strategies, and evolving trade policies. The cumulative pressures from tariff shifts and supply-chain realignments underscore the necessity of proactive risk management, including diversified sourcing and closer integration between inpatient and outpatient care channels.

Looking ahead, organizations that invest in resilient manufacturing, targeted clinical education, robust stewardship, and strategic partnerships will be best positioned to sustain access and improve clinical outcomes. By translating analytical insight into pragmatic interventions-ranging from contracting innovations to diagnostic-enabled care pathways-stakeholders can navigate the complex landscape more effectively and ensure that patients receive timely, evidence-based therapy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cryptococcosis Treatment Market, by Drug Class

  • 8.1. Azoles
    • 8.1.1. Fluconazole
    • 8.1.2. Posaconazole
    • 8.1.3. Voriconazole
  • 8.2. Flucytosine
  • 8.3. Polyenes
    • 8.3.1. Amphotericin B Deoxycholate
    • 8.3.2. Liposomal Amphotericin B

9. Cryptococcosis Treatment Market, by Administration Route

  • 9.1. Intravenous
    • 9.1.1. Central Line
    • 9.1.2. Peripheral
  • 9.2. Oral
    • 9.2.1. Suspension
    • 9.2.2. Tablet

10. Cryptococcosis Treatment Market, by Patient Type

  • 10.1. HIV Infected
  • 10.2. Non-HIV Infected
    • 10.2.1. Immunocompetent
    • 10.2.2. Transplant Patients

11. Cryptococcosis Treatment Market, by End User

  • 11.1. Clinics
    • 11.1.1. Outpatient Clinics
    • 11.1.2. Specialist Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Cryptococcosis Treatment Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Cryptococcosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cryptococcosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cryptococcosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cryptococcosis Treatment Market

17. China Cryptococcosis Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amplyx Pharmaceuticals, Inc.
  • 18.6. Astellas Pharma Inc.
  • 18.7. Bausch Health Companies Inc.
  • 18.8. Bristol-Myers Squibb Company
  • 18.9. Cipla Limited
  • 18.10. Dr. Reddy's Laboratories Ltd.
  • 18.11. F2G Limited
  • 18.12. Flynn Pharma Ltd.
  • 18.13. Gilead Sciences, Inc.
  • 18.14. Glenmark Pharmaceuticals Limited
  • 18.15. Janssen Pharmaceuticals, Inc.
  • 18.16. Lupin Limited
  • 18.17. Merck & Co., Inc.
  • 18.18. Novartis AG
  • 18.19. NuCare Pharmaceuticals, Inc.
  • 18.20. Pfizer Inc.
  • 18.21. Sigmapharm Laboratories LLC
  • 18.22. Sun Pharmaceutical Industries Limited
  • 18.23. Teva Pharmaceutical Industries Ltd.
  • 18.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 205. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 207. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 238. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 241. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 243. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 249. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 250. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 253. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 255. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)